Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$10.12 USD
+0.19 (1.91%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $10.13 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
LQDA 10.12 +0.19(1.91%)
Will LQDA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LQDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LQDA
Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?
Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock?
LQDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
Other News for LQDA
Court Finds United Therapeutics? Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
Liquidia says court finds United's interference caused losses over $137M
Caligan Partners LP Bolsters Portfolio with Significant Stake in Liquidia Corp
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
Liquidia stock rises after it prices public and private offering